For patients with atherosclerotic renal artery stenosis, what does the CORAL trial recommend regarding routine renal artery stenting versus optimal medical therapy?

CORAL Trial Recommendation: Medical Therapy Over Routine Stenting for Atherosclerotic Renal Artery Stenosis

Patients with atherosclerotic renal artery stenosis should be primarily managed with optimal medical therapy alone, as the CORAL trial definitively demonstrated that renal artery stenting offers no benefit over medical therapy for preventing cardiovascular or renal events, mortality, or meaningful blood pressure reduction. 1, 2

Key CORAL Trial Findings

The CORAL trial enrolled 947 patients with severe atherosclerotic renal artery stenosis (≥80% stenosis or ≥60% with hemodynamic gradients) who had either uncontrolled hypertension on ≥2 medications or declining renal function. After median follow-up of 43 months 1, 2:

• No difference in primary composite outcome (cardiovascular/renal death, MI, stroke, heart failure hospitalization, progressive renal dysfunction, or need for dialysis): 35.8% with medical therapy alone vs 35.1% with stenting + medical therapy (HR 0.94; 95% CI 0.76-1.17; P=0.58) 2
• No difference in any individual component of the primary endpoint 2
• Trivial blood pressure reduction with stenting: only -2.3 mm Hg systolic difference (95% CI -4.4 to -0.2) 1, 2
• No quality of life benefit from stenting 3

Meta-analyses incorporating CORAL with 7 other trials (total 2,223 patients) confirmed no favorable effects on mortality, stroke, heart failure, or renal preservation 1.

Optimal Medical Therapy Protocol

Based on the CORAL trial protocol, comprehensive medical management must include 4, 5:

1. Antihypertensive regimen including a renin-angiotensin system blocker (ACE inhibitor or ARB)
2. High-intensity statin for LDL cholesterol reduction
3. Antiplatelet therapy (aspirin or clopidogrel)
4. Smoking cessation if applicable
5. Glycemic control (HgbA1c reduction in diabetics)
6. Blood pressure target <140/90 mm Hg 1, 6, 7

Limited Exceptions: When to Consider Stenting

Renal artery stenting may be considered only in highly select circumstances (Grade D evidence) 1, 6, 4, 7:

Three Specific Clinical Scenarios:

1. Resistant hypertension uncontrolled despite maximally tolerated doses of ≥3 antihypertensive medications (including a diuretic)
2. Progressive renal function loss despite optimal medical therapy
3. Recurrent flash pulmonary edema or cardiac destabilization syndromes (Pickering syndrome)

Critical Caveat - Patient Selection Matters:

Post-hoc CORAL analyses suggest potential benefit only in patients with 8, 9:

• Low baseline albuminuria (urine albumin/creatinine ratio ≤22.5 mg/g): 5-year event-free survival 73% with stenting vs 59% with medical therapy alone (P=0.02)
• Absence of diabetes (diabetes independently predicted failure to improve renal function after stenting)
• Higher baseline eGFR correlated with better outcomes

Conversely, high albuminuria predicts poor stenting outcomes and these patients should receive medical therapy only 8.

Important Distinctions

Atherosclerotic vs Fibromuscular Dysplasia:

The CORAL recommendations apply only to atherosclerotic renal artery stenosis. For fibromuscular dysplasia 6, 4, 5:

• Renal artery angioplasty WITHOUT stenting is recommended (Class IIa)
• Can be curative, especially in younger patients with recent-onset hypertension
• Predominantly affects women (90%), mean age 53 years
• Stenting only if periprocedural dissection occurs

Clinical Algorithm

For patients with confirmed atherosclerotic renal artery stenosis:

1. Initiate comprehensive medical therapy (as outlined above) - this is the standard of care
2. Monitor response over 3-6 months
3. Consider stenting referral ONLY if:
   • Truly resistant hypertension (≥3 drugs at maximal tolerated doses including diuretic) AND
   • Low albuminuria (urine albumin/creatinine ratio <30 mg/g) AND
   • Absence of diabetes AND
   • One of: progressive renal decline OR recurrent flash pulmonary edema
4. Confirm hemodynamic significance before any intervention: ≥70% stenosis OR 50-69% stenosis with post-stenotic dilation and/or significant trans-stenotic pressure gradient 10, 11

Common Pitfalls to Avoid

• Do not routinely screen for renal artery stenosis in hypertensive patients - the prevalence of hemodynamically significant disease is only 0.1-5% 4
• Do not assume stenting will cure hypertension - even in responders, benefit is modest
• Do not stent based on anatomy alone - hemodynamic confirmation is essential for 50-69% stenoses 11
• Do not use stenting as first-line therapy - this contradicts all current guidelines 1, 6, 4, 7

The 2024 ESC guidelines 10 and 2025 AHA/ACC guidelines 4, 5 align with Canadian recommendations, emphasizing that the CORAL trial fundamentally changed practice by demonstrating medical therapy superiority for the vast majority of patients with atherosclerotic renal artery stenosis.